Acute kidney injury (AKI) is estimated to occur in about 20–200 per million population in the community, 7–18% of patients in hospital, and approximately 50% of patients admitted to the intensive care unit (ICU). Importantly, AKI is associated with morbidity and mortality; an estimated 2 million people worldwide die of AKI every year, whereas AKI survivors are at increased risk of developing chronic kidney disease (CKD) and end-stage renal disease (ESRD) — conditions that carry a high economic, societal and personal burden.

Over the past 15 years, consensus definitions have been reached for both AKI and CKD; these definitions are now routinely used in research and clinical practice. The KDIGO guideline defines AKI as an abrupt decrease in kidney function occurring over 7 days or less, whereas CKD is defined by the persistence of kidney disease for a period of >90 days. AKI and CKD are increasingly recognized as related entities and in some instances probably represent a continuum of the disease process. For patients in whom pathophysiologic processes are ongoing, the term acute kidney disease (AKD) has been proposed to define the course of disease after AKI; however, definitions of AKD and strategies for the management of patients with AKD are not currently available. In this consensus statement, the Acute Disease Quality Initiative (ADQI) proposes definitions, staging criteria for AKD, and strategies for the management of affected patients. We also make recommendations for areas of future research, which aim to improve understanding of the underlying processes and improve outcomes for patients with AKD.
A consensus definition of AKD, a staging system, and recommendations for approaches to clinical management. As the link between AKI and CKD is firmly established, the AKD period represents the time window wherein critical interventions might be initiated to alter the natural history of kidney disease. To develop a common framework and support further research for acute and progressive kidney disease, the 16th Acute Disease Quality Initiative (ADQI) sought to propose definitions and staging criteria for AKD and renal recovery and make recommendations for clinical practice and future research.

Figure 1 | Acute kidney injury and chronic kidney disease. Acute kidney injury and chronic kidney disease often form a continuum of disease as opposed to being separate entities. The various disease modifiers and risk factors might represent opportunities to intervene and mitigate the poor outcomes associated with these diseases. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org.

Methods
The Conference Chairs of the 16th ADQI consensus committee (L.S.C., J.A.K. and C.R.) convened a diverse panel of clinicians and researchers representing relevant disciplines — internal medicine, primary care, nephrology, critical care, pediatrics, pharmacy, epidemiology, health-services research, biostatistics, bioinformatics and data analytics — from Europe, North America and Australia, to discuss the issues relating to persistent AKI and renal recovery. The conference was held over 2.5 days in San Diego, USA on November 8–10, 2015.

This consensus meeting followed the established ADQI process, and used a modified Delphi method to achieve consensus, as previously described. The broad objective of ADQI 16 was to produce expert-based statements and a summary of current knowledge pertaining to the definition and management of AKD for use by clinicians and researchers according to ADQI’s professional judgment and to identify evidence gaps to establish research priorities. Conference participants were divided into four work groups, which were tasked with formulating strategies for the initial workup and management of AKD and renal recovery in four different areas: Group 1 was tasked with developing recommendations for defining persistent AKI and AKD. Group 2 was tasked with developing definitions and staging for AKD. Group 3 developed recommendations for the management of patients with AKI and/or AKD requiring renal replacement therapy (RRT). Group 4 was tasked with developing recommendations for the management of medications among patients with AKD. Members of the work groups performed reviews of the literature in a systematic manner and developed a consensus of opinion, backed by evidence where possible, to distill the available literature and articulate a research agenda to address important unanswered questions. In addition, the members were asked to note the level of evidence for all consensus statements using the Oxford Centre for Evidence-based Medicine Levels of Evidence. All of the individual workgroups iteratively presented their output to conference participants and the final product was then assessed and aggregated in a session attended by all attendees, who formally voted and approved the consensus recommendations. Discussion of the use of peritoneal dialysis as an option for treating AKI was
Injury

0 1 2 7 90 180
(48h)

Days post injury

Figure 2 | The continuum of acute kidney injury (AKI), acute kidney disease (AKD) and chronic kidney disease (CKD). AKI, AKD and CKD can form a continuum whereby initial kidney injury can lead to persistent renal injury, eventually leading to CKD. AKI is defined as an abrupt decrease in kidney function occurring over 7 days or less, whereas CKD is defined by the persistence of kidney disease for a period of >90 days. AKD describes acute or subacute damage and/or loss of kidney function for a duration of between 7 and 90 days after exposure to an AKI initiating event. Recovery from AKI within 48 h of the initiating event typically heralds rapid reversal of AKI. For patients with pre-existing CKD, the AKI event can be superimposed on CKD, with AKD existing on a background of CKD. Patients who suffer AKD with pre-existing CKD are probably at high-risk of kidney disease progression. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org.

Box 1 | Definitions of AKI and AKD, initial management of AKI, and assessment of kidney function

Consensus statement 1A:
Persistent acute kidney injury (AKI) is characterized by the continuance of AKI by serum creatinine or urine output criteria (as defined by KDIGO) beyond 48 h from AKI onset. Complete reversal of AKI by KDIGO criteria within 48 h of AKI onset characterizes rapid reversal of AKI (evidence grade: level 5).

Consensus statement 1B:
Although the optimal duration of sustained AKI reversal is unknown, a minimum of 48 h is necessary to separate two distinct AKI episodes (evidence grade: level 5).

Consensus statement 1C:
AKI and acute kidney disease (AKD) are a continuum, and persistent AKI frequently becomes AKD, defined as a condition wherein criteria for AKI stage 1 or greater persists ≥7 days after an exposure (FIG. 2; TABLE 1; evidence grade: level 4).

Consensus statement 1D:
Initial management of persistent AKI should include reassessment of the underlying aetiology of AKI and precise measurement of kidney function. When persistent AKI is diagnosed, additional monitoring should be considered to re-evaluate haemodynamic and volume status, adequacy of kidney perfusion, and to identify complications of AKI, such as fluid overload, acidosis and hyperkalaemia, as these could indicate a need for renal replacement therapy. Nephrology consultation should be considered if the aetiology of AKI is not clear or subspecialist care is needed (evidence grade: level 5).

Consensus statement 1E:
An urgent need exists for clinical tools to enable the precise measurement of kidney function in the setting of AKI as existing tools are impractical for routine clinical use. At present, timed urine creatinine clearance is the best available estimate of kidney function for patients with persistent AKI in the steady state (evidence grade: level 4).

Consensus statement 1F:
Equations to estimate glomerular filtration rate in the setting of chronic kidney disease are not accurate for the assessment of renal function in persistent AKI (evidence grade: level 4).
contributing factors. This time period of 48 h to separate distinct AKI episodes is arbitrary and will require further study and validation.

**Identification of persistent AKI**

Early identification of persistent AKI is important in order to initiate an extended evaluation and management protocol to avoid further kidney damage and associated mortality. An array of tools including clinical scoring systems, imaging approaches, and biomarkers must be developed to identify patients at risk of persistent AKI. A 2016 study of nearly 17,000 patients demonstrated that persistence of AKI and a stuttering versus prompt recovery pattern are linked to morbidity and mortality. Importantly, these data suggest that interventions that alter the recovery pattern of AKI have the potential to improve patient outcomes. As most patients with severe sepsis — an important cause of AKI — present to the hospital with ongoing AKI, approaches to mitigate injury and enhance recovery from AKI should be areas of immediate focus. However, clinical risk scores for persistent AKI have not been validated for general use and the risk factors that contribute to persistent AKI, AKD, and delayed recovery among hospitalized patients are not known. Several studies have identified clinical risk scores, biomarkers, imaging, and functional tests to differentiate rapid reversal of AKI from persisting AKI (see Supplementary information S2 (table)). In the opinion of the ADQI workgroup, these tools would likely work well together and are a recommended area of future research (BOX 2).

**Management of persistent AKI**

Persistent AKI occurs in a subset of patients with AKI; given the poor outcomes associated with persistent AKI, the ADQI workgroup recommends the presence of persistent AKI as a wake-up call to initiate further assessment and evaluation of treatment options. When a diagnosis of persistent AKI is made, the clinician should reassess the patient carefully and reconsider treatment options. First, the etiology of the AKI should be considered. In most cases this etiology is multifactorial, and it will occur secondary to another disease (for example, sepsis or shock) and notably can occur in early, middle, or late phases of the patient's hospital stay. A diagnosis of persistent AKI should prompt re-evaluation of the possible causes of AKI, and correction of the underlying cause(s) when possible. Identification of potential causes of AKI might require additional tests such as evaluation of urine sediment, proteinuria, biomarker assessment and/or imaging. In select circumstances, consultation of other specialties might be needed to help diagnose rare causes of AKI (for example, caused by tumour lysis syndrome, thrombotic thrombocytopenic purpura and cholesterol embolization syndrome).

**Approaches to assess renal function.** Current approaches to measure glomerular filtration rate (GFR) with inulin, $^{51}$Cr-EDTA, or iohexol are time-consuming and laborious, and are therefore unsuitable for use in patients in intensive care. Equations for estimated GFR (eGFR), such as the modification of diet in renal disease (MDRD) or chronic kidney disease epidemiology collaboration (CKD–EPI) equations, were validated in patients with CKD. These equations can be used in the outpatient setting but not in the ICU setting, because they require serum creatinine to be in ‘steady-state’ (REF. 29). As an alternative, short timed urine creatinine clearance (CCR) can be used to estimate GFR. However, several limitations exist to the use of CCR in ICU patients. For instance, CCR will often overestimate GFR, especially in patients with AKI, as creatinine is also excreted in the tubules, and establishing steady state conditions is often not possible.

Some additional approaches to estimate GFR deserve further exploration. The Jelliffe equation for unstable kidney function, which is calculated on the basis of the volume of distribution and creatinine kinetics rather than steady state parameters such as body weight or age, correlated well with CCR in a small study of 12 patients in the ICU. The kinetic eGFR, which similarly to the Jelliffe equation, estimates GFR on the basis of the creatinine kinetics has shown promise in renal transplant recipients, but should be validated in other cohorts such as hospitalized patients with native kidneys. Iohexol clearance has been used in critically ill patients but as mentioned above, is laborious and time consuming. Finally, fibreoptic ratiometric fluorescence analysis has shown promise for the measurement of GFR in large animals but awaits validation in human clinical settings.

---

**Box 2 | Research recommendations to aid the assessment of persistent AKI and AKD**

**Consensus statement 1H:**
An array of tools (such as clinical risk scores, imaging techniques, functional testing, and biomarkers) are needed to identify patients who are likely to have persistent acute kidney injury (AKI; evidence grade: level 5).

**Consensus statement 1I:**
Alternative approaches for estimating glomerular filtration rate (GFR), such as kinetic GFR and the Jeliffe equation need to be further evaluated in different patient populations (research recommendation).

**Consensus statement 1J:**
Additional studies are needed to elucidate the relationship between biomarkers of glomerular and tubular damage and outcomes of persistent AKI and acute kidney disease (AKD; research recommendation).

**Consensus statement 1K:**
The existing and emerging approaches for risk stratification of persistent AKI need to be further evaluated (research recommendation).
Given that patients who have persistent AKI have worse outcomes than those of patients who recover from AKI, the ability to predict the clinical course of AKI with use of biomarkers of tubular or glomerular injury might help to differentiate these patients from those who will recover and enable prediction of outcomes. We therefore recommend that further research relating to biomarkers and renal functional tests should focus on this cohort of patients with AKI (BOX 2).

From a treatment standpoint, patients with persistent AKI should be re-assessed on a daily basis bearing in mind at least two key considerations. First, the ongoing volume needs of the patient and risk of volume overload, and second, an assessment of the necessity of nephrotoxic medications and their appropriate dosing, balancing the risk of AKI and the benefits of each individual drug for the patient. Optimization of haemodynamic and volume status are important for the resolution of AKI, and these parameters should be evaluated closely.

**Baseline creatinine assessment**

The best method for assessing baseline creatinine level can be uncertain given the inherent biologic variation in serum creatinine and the fact that serum creatinine measurements are made only when clinically indicated. Although no approach to the assessment of baseline creatinine is perfect, the goal should be to reduce bias in anchoring the definition of AKD and its recovery. Towards that end, the use of known creatinine values is superior to imputation. For patients in whom one or more pre-morbid serum creatinine values are available but show significant fluctuation, the choice of the serum creatinine measurement that best reflects the most appropriate baseline value may require adjudication by an expert clinician. In a large dataset, the mean serum creatinine value assessed 7–365 days before admission closely approximated expert clinical adjudication of baseline creatinine level. Differences in misclassification were, however, modest compared with other available creatinine values, including the measurement taken at the time closest to hospital admission compared to the previous 7–365 days, which might be preferable in certain populations such as in patients undergoing elective surgery, those with progressive CKD, or those with a recent history of AKI.

For patients in whom no pre-morbid serum creatinine values are available, various methods for estimating these values have been studied, including imputing previous values. Knowing the strengths and limitations of each approach is key to interpreting future study findings. For example, the accuracy of estimating a creatinine value using back-calculation from an eGFR of 75 ml/min/1.73 m² has been previously studied. This approach is likely the most sensitive for detecting AKI among patients with no premorbid serum creatinine value and is anticipated to work well in populations with largely preserved kidney function. In populations with a high prevalence of risk factors for CKD, however, this method might overestimate the incidence and severity of AKI and, therefore, AKD.

**Acute kidney disease**

AKI is a risk factor for the future loss of kidney function, cardiovascular disease, and death. Defining optimal follow-up care for this high-risk population is therefore essential, especially during the transition of care beyond the acute care setting when recovery from AKI and its underlying precipitants might be ongoing. In this section, we examine surveillance approaches and interventions for survivors of AKI from hospital discharge to 90 days after the onset of renal dysfunction, identify knowledge gaps in the current understanding of AKD and its trajectories, and suggest approaches to address these knowledge gaps with the aim of defining approaches for the care of these individuals. We also propose an operational framework for AKD, which integrates with the KDIGO AKI classification scheme to characterize changes in kidney function or injury that do not meet strict criteria for AKI or CKD, including important patient-centred outcomes such as renal recovery. Here, we present three key concepts with regard to the follow-up of patients with AKD and a series of consensus statements developed through literature review and agreement within the ADQI workgroup.

**Definition of AKD**

AKD is defined as a condition in which AKI stage 1 or greater, as defined by KDIGO, is present ≥7 days after an AKI initiating event. AKD that persists beyond 90 days is considered to be CKD (BOX 3). An AKI initiating event can usually be identified but is not required to diagnose AKD. Typical scenarios in which patients may present with AKD

<table>
<thead>
<tr>
<th>Box 3</th>
<th>Definition of AKD and recovery from AKD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Consensus statement 2A:</strong></td>
<td>- Acute kidney disease (AKD) describes acute or subacute damage and/or loss of kidney function for a duration of between 7 and 90 days after exposure to an acute kidney injury (AKI) initiating event.</td>
</tr>
<tr>
<td><strong>Consensus statement 2B:</strong></td>
<td>- Outcomes of AKD include recovery, recurrence of AKI, progression of AKD and/or death.</td>
</tr>
<tr>
<td><strong>Consensus statement 2C:</strong></td>
<td>- AKD that persists beyond 90 days is considered to be chronic kidney disease.</td>
</tr>
<tr>
<td><strong>Consensus statement 2D:</strong></td>
<td>- Recovery from AKD can be operationally defined as a reduction in peak AKI stage (based on KDIGO criteria) and can be further refined by change in serum creatinine level, glomerular filtration rate, biomarkers of injury or repair, and/or return of renal reserve (evidence grade: level 5).</td>
</tr>
<tr>
<td><strong>Consensus statement 2E:</strong></td>
<td>- The care of patients with AKD after hospital discharge is inadequately characterized. Limited observational data suggest that survivors of AKI will be cared for by a diverse group of providers, with some patients not receiving timely assessment of kidney function, ongoing kidney damage, or associated complications (evidence grade: level 5).</td>
</tr>
<tr>
<td><strong>Consensus statement 2F:</strong></td>
<td>- Limited evidence exists to guide the practice of routine follow-up for patients with AKD. Standards for the evaluation of kidney function, risk identification, surveillance for complications of AKD, and determining whether the risk for future adverse outcomes can be reduced are needed (evidence grade: level 5).</td>
</tr>
</tbody>
</table>
CONSENSUS STATEMENT

Figure 3 | Hypothetical trajectories of acute kidney disease (AKD). AKD follows on from acute kidney injury (AKI) in those patients who do not fully recover within 7 days. The trajectory of AKD can take many forms largely depending on the severity of the initial AKI episode. Here, a series of hypothetical scenarios representing typical trajectories of the AKI–AKD continuum are depicted. Stage 3 AKI might slowly improve to stage 2 AKI and then progress to AKD (1). Stage 1 AKI might progress to stage 3, then improve rapidly to stage 1 AKI before progressing to stage 1 AKD (2). An episode of persistent AKI (>48 h) might be followed by a period of sustained reversal (*), then a second episode of AKI (?) leading to AKD (3). Stage 2 AKI might rapidly reverse (4). Subacute AKD might occur wherein the first 7 days are marked with slowly worsening renal function that does not technically meet the criteria for AKI, and progress to Stage 3 AKD (5). This trajectory can be seen in patients treated with chronic nephrotoxic medications (for example, with aminoglycosides). Modified from Acute Dialysis Quality Initiative 16; www.adqi.org.

include instances in which AKI is observed and the patient remains in KDIGO stage 1 or greater after 7 days; instances in which an episode of AKI was not observed (for example, in patients with community-acquired AKI*), but inferred by the persistence of kidney disease beyond 7 days (for patients without a known baseline creatinine value, clinical adjudication of AKD versus CKD might be required); instances in which subacute AKI, documented by either histology, imaging, proven biomarkers, or a relevant exposure (such as to a nephrotoxin), does not meet criteria for AKI or CKD; and instances in which AKI is observed, partially improves and then progresses after 7 days** (FIGS 2, 3).

In 2012, the KDIGO AKI workgroup proposed the term AKD to define any acute condition that impacts kidney function including AKI, eGFR <60 ml/min/1.73 m², a decrease in GFR by >35%, an increase in serum creatinine of >50%, or any kidney damage lasting <3 months*. The goal of this operational definition was to “provide an integrated clinical approach to patients with acute abnormalities of kidney function and structure” and help to unify the more established concepts of AKI and CKD. Herein, the ADQI workgroup propose a new definition of AKD to further refine these criteria; we have also added a staging system. Our conceptual framework of AKD attempts to capture the entire spectrum of acute and subacute disease (including AKI), beginning with the initiation of injury (FIG. 2), as recognized using either conventional or novel markers of injury, its evolution, and kidney end points up to 90 days after the onset of injury. This updated AKD classification has two main features. First, it recognizes an important population of patients with evolving kidney disease who might not fulfil strict criteria for AKI (or CKD), such as those with kidney disease the onset of which is uncertain or subacute. Second, it highlights that the process of AKD can include AKI and extends beyond mere detection and staging of disease through the process of recovery or worsening until criteria for incident or worsening CKD are reached.

Various hypothetical trajectories of AKI exist (FIG. 3); however, important knowledge gaps need to be addressed before AKD terminology can be meaningfully used in clinical practice*†‡ (BOX 4). To date, only one study has attempted to characterize AKD using kidney biopsy samples*. Although the study findings suggest that the distribution of aetiologies that contribute to AKD without AKI might differ from those that contribute to AKI alone, the population studied (273 patients in China) was selected for clinical indications for biopsy and is likely not reflective of the

Box 4 | Research recommendations for AKD

Further studies are needed to:

Consensus statement 2F:
- Describe the epidemiology, clinical course and natural history of patients who fulfill criteria for acute kidney disease (AKD).
- Describe the biological and structural changes in kidney function of patients who fulfill criteria for AKD.
- Describe the discrete phenotypes of trajectories of outcomes at 90 days among patients fulfilling criteria for AKD and their association with future adverse sequelae.

Consensus statement 2G:
- Describe the susceptibilities and modifying factors that affect the timeline and staging of recovery among of patients who fulfill the criteria for AKD.
- Determine optimal methods to assess functional recovery and identify novel biomarker(s), functional tests, and imaging approaches that can inform ongoing injury and repair in AKD.
- Identify patients at highest risk of the adverse sequelae of AKD and identify modifiable risk factors that can be tested formally in clinical trials.

Consensus statement 2H:
Characterize patterns of care experienced by AKD survivors following hospital discharge.
Figure 4 | Interplay between acute kidney injury (AKI), acute kidney disease (AKD) and chronic kidney disease (CKD). AKI stages map directly to the new proposed AKD stages. In addition, patients with AKD can progress to CKD. Stage 0 AKD represents partial recovery from AKI. Stage 0C includes patients for whom serum creatinine levels are higher than baseline but within 1.5 times baseline levels. Stage 0B includes patients whose serum creatinine has returned to baseline levels, but who still have evidence of ongoing kidney damage, injury, or loss of renal reserve. Stage 0A includes those patients who have had an episode of AKI and retain a risk of long-term events without structural or damage markers for AKD. Patients whose serum creatinine level has not returned to baseline and who have ongoing evidence of kidney damage and/or injury are termed stage 0B/C.

broader population of patients with AKD. Further work is warranted to delineate the epidemiology of AKD, including differences in the predictors, course, and outcomes relative to AKI. Few data exist on characterizing the phases of AKD, including the processes by which patients recover or progress to CKD, the evolving risk experienced by AKD survivors, and the processes of care experienced.

For the purposes of our recommendations, AKD is conceptualized not as pre-CKD but rather, as post-AKI. This distinction has important implications for the diagnosis, care and follow-up of affected patients, including the notion that AKD might exist even in the absence of standard clinical evidence (FIGS 2, 4).

The ideal definition for recovery should quantify lost pre-existing kidney function as well as current residual kidney function and reserve, identify when recovery is complete, and provide prognostic information (BOX 3). Intrinsic to the concept of AKD is that acute loss of kidney function or damage extends beyond diagnosis and staging of AKI and highlights additional points of potential intervention from the onset of injury through to the more convalescent phase of disease that could modify long-term outcomes. No standardized definition of recovery from AKI or AKD exists, and only a few studies have evaluated the kinetics or trajectory of recovery from either AKI or AKD among patients not on dialysis (see Supplementary information S3 (table)). Although these studies have used varying time frames and thresholds of serum creatinine level to define recovery, the results generally show a graded association between recovery and future risk of mortality, loss of kidney function, and other morbidities.

Other potential measures of recovery

AKD and recovery from AKD are currently assessed using filtration markers, such as serum creatinine. This approach has limitations, however, and loss of muscle mass, changes in volume of distribution, changes in renal reserve, and hyperfiltration can confound the assessment of functional recovery. Methods to assess glomerular functional reserve (for example, by assessing the effect of a protein load on GFR) or tubular functional reserve (for example, through furosemide stress testing or the administration of intravenous creatinine) have also been developed in the CKD setting but have yet to be applied to patients with AKD. Interestingly, serum creatinine level has been the standard approach to the assessment of renal function for decades, but intravenously administered creatinine fails to increase GFR in humans, regardless of renal function. Intravenous creatinine does, however, significantly increase creatinine clearance, demonstrating that glomerular and tubular reserve do not necessarily correlate and suggesting that patients with CKD can maintain some preservation of glomerular renal reserve but fail to show any measurable tubular reserve. On the basis of these findings, assessments of glomerular and tubular reserve are likely to assess different facets of kidney disease. Several studies have also examined the use of next-generation biomarkers of tubular injury and furosemide stress testing to predict recovery from AKI. As many of these markers reflect ongoing tubular injury, most studies have focused on their ability to indicate the likelihood of recovery during early or peak AKI in select groups of patients (see Supplementary information S4 (table)). Further work is needed to determine the utility of these biomarkers in informing clinical decision-making.

A framework to classify AKD and recovery

A useful classification of recovery from AKD would quantify the extent to which kidney function was lost, indicate when repair is complete and damage is no longer occurring, provide a measure of a patient’s current kidney function and reserve, and provide prognostic information. A scheme that aligns with and integrates the KDIGO categories for AKI and provides a simple and translatable framework for ascertaining transition points for outcomes during AKD and at the end of 90 days would be ideal. Accordingly, we propose to map the KDIGO AKI staging categories to the staging of AKD for the purpose of defining the severity of AKD and to offer a framework for kidney-specific outcomes across a 90-day timeline (FIG. 4).

In this conceptual framework, improvements in kidney function and/or resolution in kidney damage would be staged by an improvement (decrease) in AKD stage (for example, a shift from stage 3 AKD to stage 2 or lower). We recognize that specific thresholds to define ‘recovery’ remain to be defined, in particular in selected populations...
such as survivors of critical illness or among patients who no longer fulfil criteria for AKI or AKD stage 1 but whose serum creatinine level has not yet returned to baseline\(^{62,74}\). In this framework, we propose a ‘stage 0’, with A, B, and C subgroups (TABLE 1). Stage 0C includes patients for whom serum creatinine levels are higher than baseline but within 1.5 times baseline levels. Population studies suggest that these patients who achieve a recovery serum creatinine level that remains above 115% of baseline levels still carry a mortality risk\(^{44}\). Thus, these patients with AKD might require further follow-up and could be candidates for future therapeutic intervention. Stage 0B includes patients whose serum creatinine has returned to their baseline level after an episode of AKI, but still have evidence of ongoing kidney damage. The diagnosis of this ongoing damage for most patients will likely be in the form of new-onset proteinuria, worsened proteinuria from baseline, new-onset hypertension, or worsening hypertension. In addition to proteinuria and hypertension, evidence of ongoing kidney disease might be assessed through use of biomarkers or imaging studies. Stage 0B also includes patients for whom serum creatinine level has returned to baseline after an episode of AKI with no evidence of ongoing kidney damage, but who have experienced a loss of renal reserve. One example of this scenario would be a patient who has undergone a nephrectomy, whereby the contralateral kidney might adapt to the loss of renal mass, but a significant portion of renal reserve has nonetheless been lost. The assessment of renal reserve can be assessed by both glomerular and tubular stress testing\(^{75}\). Patients in whom serum creatinine levels fail to return to baseline and have evidence of ongoing injury would be classified as having Stage 0B/C. As the study of AKD is nascent, future research should carefully assess the risk of future events associated with these AKD stages (BOX 4). In addition, the thresholds of the various biomarkers, imaging outputs, and/or renal reserve that define ‘full recovery’ versus ongoing risk is not known and will require further investigation. Stage 0A encompasses patients who have no evidence of damage or functional loss following an AKI episode and represents clinical recovery. These patients may nonetheless be vulnerable to further kidney damage and other adverse events. As has been shown previously, patients who have suffered an AKI event and ‘recover’ still carry a long-term increased risk of major adverse cardiac and kidney events\(^{49,77}\). Patients with AKD stage 0A might still require follow-up and could likely benefit from avoiding unnecessary nephrotoxic drugs. We hypothesize that this framework will enable the recognition and description of the dynamic nature of AKI and AKD beyond the initial diagnosis and staging of kidney injury, which will enable improved understanding of the natural course of the disease and ultimately facilitate the development of specific care pathways to guide surveillance, investigation and interventions, and align with care beyond 90 days. However, the accuracy and usefulness of these proposed stages in assessing kidney function and damage in patients with AKD requires further validation.

Finally, in keeping with the original conceptual framework for AKD as proposed by KDIGO, we recognize that AKI might not have always been diagnosed in a patient who appears to have an acute deterioration in renal function. In other words, the diagnosis of AKD may require inference of the existence of an episode of AKI. For example, consider a patient who is seen for an annual internist visit. The patient’s serum creatinine is found to be twice the level observed the year before and they describe a severe ‘flu-like’ illness 2 months prior that lasted a week but eventually resolved without medical attention. We would suggest that treating this situation as a likely case of AKD — for example, by requesting that the patient avoids unnecessary nephrotoxic drugs, requesting follow-up serum creatinine measurements, and screening for CKD risk factors — would be reasonable.

**Follow-up care**

As the evidence linking AKI with loss of kidney function\(^{45–47,77–80}\), hypertension\(^{81,82}\), cardiovascular disease\(^{49,50,83}\), and death\(^{46,83–87}\) accumulates, determining the optimal care for this growing population is critical. The American Society of Nephrology AKI Advisory Group has highlighted the transition of care as a potential opportunity to reduce the long-term impact of AKI\(^{44}\), and hence, AKD. However, a paucity of data exists to indicate which interventions can reduce morbidity and mortality in AKI/AKD survivors.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Stage 0* | A: Absence of criteria for B or C.  
B: Continued evidence of ongoing injury, repair and/or regeneration or indicators of loss of renal glomerular or tubular reserve  
C: Serum creatinine level < 1.5 times baseline but not back to baseline levels  
B/C: Serum creatinine level < 1.5 times baseline but not back to baseline levels, and continued evidence of ongoing injury, repair and/or regeneration |
| Stage 1 | Serum creatinine level 1.5–1.9 times baseline |
| Stage 2 | Serum creatinine level 2.0–2.9 times baseline |
| Stage 3 | Serum creatinine level 3.0 times baseline or increase in serum creatinine to ≥353.6 μmol/l (≥4.0 mg/dl) or ongoing need for renal replacement therapy |

*Reflects that even when no apparent residual injury is present, the kidney might be vulnerable for some time after an episode of AKI. Assumes the baseline serum creatinine level is <353.6 μmol/l (<4.0 mg/dl), and that an episode of AKI has occurred. AKD, acute kidney disease; AKI, acute kidney injury.
A first step in developing effective care strategies is to understand how care during follow-up associates with long-term outcomes. One element that has been examined is which physicians care for patients with AKI following hospital discharge. Studies indicate that most survivors of AKI are not cared for by nephrologists. Although data derived largely from observational cohort studies suggest that referral to nephrology care is associated with improved survival, causality remains to be proven and the elements of care that drive this potential benefit have not been identified. Identifying the driver(s) of beneficial outcomes is of critical relevance as rapid growth in the incidence of AKD means that most survivors will be cared for initially by primary care physicians.

One potential process of care that might confer benefit during follow-up is close monitoring of kidney function. Currently, a lack of evidence exists to guide the timing, frequency, and methods to evaluate kidney function among patients following an episode of AKI. Current KDIGO guidelines recommend that patients are evaluated "3 months after AKI for resolution, new onset, or worsening of pre-existing CKD". Data from Medicare claims and the Veterans Affairs database indicate that only 50–69% of patients have a serum creatinine level measured within 3 months of an episode of AKI and that assessment of proteinuria occurs even more infrequently. We recommend that the intensity of surveillance should be proportionate to the risk of future outcomes (FIG. 5). For example, patients who have more severe or persistent AKD, those with premorbid conditions that increase the risk of future CKD progression (for example, those with evidence of pre-existing CKD, diabetes and/or proteinuria), and those with recurrent disease or non-recovery (for example, those with congestive heart failure, cirrhosis, and/or malignancy) might achieve greater benefit from earlier or more frequent surveillance than patients with a lower risk of future CKD. This hypothesis is supported by data showing that rates of re-hospitalization and recurrent AKI are high among patients with similar risk factors.

We propose a conceptual ‘layered’ approach to the follow-up of patients with AKD whereby the intensity of care rises in proportion to the risk of intermediate and long-term morbidity and mortality (FIGS 5–6). Improving patient awareness of AKD and conditions or symptoms that might require evaluation of kidney function (such as oedema and volume-depleting illness), documenting that AKI and/or AKD has occurred particularly if moderate to severe or persistent, and processes of care including medication reconciliation to facilitate appropriate dosing and nephrotoxin avoidance, might help to alert future care providers to the risk of AKD. Reduce the risk of adverse events including recurrent AKI, and potentially improve the probability of recovery.

RRT recommendations for patients with CKD

The decision of when to initiate RRT is not standardized between countries, institutions or even between individual physicians within a group practice. Although initiation of RRT is usually associated with serious renal dysfunction corresponding to stage 3 AKI as defined by KDIGO, some instances exist in which RRT is initiated in the setting of non-severe renal dysfunction, for example, in the setting of electrolyte disturbances, fluid overload, toxic ingestions or poisoning. Thus, database studies that use RRT as an indicator of severe AKI might also include a small proportion of patients with less severe AKI. Nonetheless, the approach of using RRT as a marker of AKI severity has yielded consistent findings across more than 1 million patients assessed worldwide and remains an excellent surrogate for severe AKI in database studies.

Assessing recovery from RRT dependence

Although current definitions for the recovery of patients from dialysis-dependent AKI are diverse and subjective, a unifying characteristic is sustained independence from RRT. We suggest that organ (kidney) recovery in patients who have received acute RRT be defined as sustained independence from RRT for a minimum of 14 days. This definition is not to say that independence from RRT cannot be assessed before 14 days and we appreciate that researchers might use various means to adjudicate independence from RRT before hospital discharge. However for individual patient care, we recommend close follow-up after hospital discharge to ensure that independence from RRT is indeed sustained.

In order to assess recovery from dialysis-dependent AKD, we suggest that laboratory and clinical evaluation after cessation of acute RRT should occur within 3 days (and no later than 7 days) after the last RRT session, and be followed by regular and frequent assessments.
AKI and include a plan for outpatient care that includes measurement and documentation of kidney function. Furthermore, continued follow-up with a nephrologist is recommended.

For patients who are discharged while still receiving RRT, frequent review and documentation of kidney function should occur to assess the continued need for RRT. At a minimum, these reviews should include a weekly assessment of serum creatinine values and regular assessment of residual kidney function using a 24 h urine collection to assess volume of urine output as well as creatinine and urea clearance. Careful consideration should be given to the temporary acute vascular access site, with avoidance of subclavian veins and the internal jugular vein on the side of a future potential arteriovenous fistula. Importantly, if the patient is discharged from the hospital to a chronic dialysis facility, the treating team should be informed that a personalized approach that maximizes the likelihood of renal recovery should be utilized. Specifically, avoidance of excessive fluid removal and hypotension are critical to prevent re-injury to the kidney and to enhance the likelihood of renal recovery.

We contend that the therapeutic goal for patients recovering from an episode of RRT-requiring AKI should be recovery of functional status to pre-morbid levels. Assessment of kidney function in patients who received RRT and recovered to RRT independence must take into account loss of muscle mass and its impact on standard markers of GFR such as serum creatinine. The use of alternative markers of GFR that are not sensitive to muscle mass (for example, cystatin C) or the direct quantification of GFR (with iohexol clearance, for instance), should be considered in selected cases.

**Predicting outcomes**

We suggest that novel biomarkers and approaches to the direct measurement of GFR might be valuable for the evaluation of kidney recovery among patients receiving RRT (BOXES 5, 6). Pending the development of such tools, the utility of available markers, such as urine

---

**Box 5 | Recommendations for the assessment of recovery in patients with RRT-dependent AKD**

**Consensus statement 3A:**
Renal recovery in patients with acute kidney injury (AKI) who are treated with acute renal replacement therapy (RRT) is defined as sustained (>14 days) independence from RRT (evidence grade: level 5).

**Consensus statement 3B:**
Current tools and diagnostics are insufficient to accurately assess kidney function in patients receiving acute RRT (evidence grade: level 5).

**Consensus statement 3C:**
Limited data exist on how to use clinical factors and diagnostic tests to reliably predict non-recovery among patients with acute kidney injury (AKI) on RRT (evidence grade: level 4).

**Consensus Statement 3D:**
Insufficient data are available to recommend specific RRT techniques to improve renal and patient recovery (evidence grade: level 4).

**Consensus Statement 3E:**
Insufficient data exist to recommend specific processes of care or techniques to improve renal and patient recovery for patients with RRT-dependent AKD (evidence grade: level 5).
metabolism), and altered pharmacokinetic parameters due to decreased kidney function (for example, volume overload and metabolic acidosis). In addition, the mechanism of nephrotoxicity, whether from direct tubular toxicity (such as caused by aminoglycosides), renooconstriction (such as caused by NSAIDs and radiocontrast media), interstitial nephritis (such as caused by NSAIDs and β-lactams) or crystallization (caused by acyclovir), should be considered in the context of the functional phase of AKD. For example, withholding NSAIDs might make sense while a patient is in the persistent or recovery phase of AKD whereas careful dosing and monitoring of aminoglycosides to prevent re-injury in the recovery phase of AKI might be warranted.

Factors that must be taken into account when selecting a treatment regimen include considerations as to the mode of drug excretion (renal versus non-renal); the potential for nephrotoxicity; the effect of AKD on drug metabolites and/or the effect of AKD on the non-renal metabolism of drugs; the strength of indications and/or urgency for their use; and the availability of suitable alternatives (BOX 7).

The relevance of each of these considerations for a particular drug is likely to vary, and once again, should be taken in the context of the AKD stage, with reassessment as patients transition from one AKD stage to another, including the identification of patients who are at risk of nephrotoxicity before exposure to the toxic agent. For instance, avoidance of nephrotoxic medications such as aminoglycosides or NSAIDs in a patient at risk of AKI (such as in patients with CKD, a previous history of AKI, or in those who are already taking multiple nephrotoxic medications), who is admitted to the ICU would make sense, unless that medication is clearly superior in terms of efficacy and no suitable alternative exists. Early in the AKI course when GFR is starting to fall, a systematic reassessment of drug dosing, surveillance of drug concentrations when available, and avoidance of nephrotoxic medications or drugs with a renovascular effect should be undertaken. Various factors relating to drug avoidance or the reintroduction of drugs in various AKD stages need to be considered (BOX 7, TABLES 3, 4).

Below, we discuss considerations relevant to angiotensin-converting-enzyme (ACE) inhibitors and

---

**Consensus Statement 3F:**

- Future research should aim to determine the optimal time to define sustained independence from renal replacement therapy (RRT) and to develop and validate functional assessment tools for this population.
- Strategies to accurately assess endogenous kidney function among patients receiving acute RRT are urgently needed. Candidate biomarkers and real-time assessment of glomerular filtration rate should be evaluated for this purpose.
- Derivation and validation of a clinical risk score to predict RRT dependence at 90 days (and possibly at subsequent time points) would be a valuable tool for patients and clinicians. A search for potentially modifiable risk factors should be prioritized as these might represent therapeutic targets for the preservation of kidney function following RRT-requiring AKI.
- Future studies involving RRT interventions should focus on kidney recovery as an important outcome measure. Clinical trials in which kidney recovery is an end point should follow patients for a minimum of 90 days. Interventions that focus on ultrafiltration intensity, fluid balance, cardiovascular stability and optimal antibiotic dosage have the most plausible likelihood of influencing renal recovery and should be prioritized.

---

**Box 6 | Research recommendations for the study of patients with RRT-requiring AKI**

**Consensus Statement 3F:**

- Future research should aim to determine the optimal time to define sustained independence from renal replacement therapy (RRT) and to develop and validate functional assessment tools for this population.
- Strategies to accurately assess endogenous kidney function among patients receiving acute RRT are urgently needed. Candidate biomarkers and real-time assessment of glomerular filtration rate should be evaluated for this purpose.
- Derivation and validation of a clinical risk score to predict RRT dependence at 90 days (and possibly at subsequent time points) would be a valuable tool for patients and clinicians. A search for potentially modifiable risk factors should be prioritized as these might represent therapeutic targets for the preservation of kidney function following RRT-requiring AKI.
- Future studies involving RRT interventions should focus on kidney recovery as an important outcome measure. Clinical trials in which kidney recovery is an end point should follow patients for a minimum of 90 days. Interventions that focus on ultrafiltration intensity, fluid balance, cardiovascular stability and optimal antibiotic dosage have the most plausible likelihood of influencing renal recovery and should be prioritized.
angiotensin-receptor blockers (ARBs), two nearly ubiquitously prescribed medications with renovascular effects.

**ACE inhibitors and ARBs**

At present the armamentarium available for facilitating the transition from AKI to recovery is limited and the decision to restrict therapies might reflect the nephrotoxic potential of some drugs. Perhaps the most relevant examples are ACE inhibitors and ARBs, which are associated with functional AKI, particularly in the setting of acute hypovolaemia. These agents are frequently prescribed, particularly in the elderly. A 2013 study from the UK that used routinely collected national hospital administrative data showed that a 16% increase in ACE inhibitor and ARB prescribing between 2007 and 2011 corresponded with a 50% increase in the number of hospital admissions complicated by AKI.

### Table 2 | RRT characteristics that might affect recovery from AKI

<table>
<thead>
<tr>
<th>RRT characteristic</th>
<th>Effect on renal recovery</th>
<th>Effect on patient recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality (intermittent, prolonged intermittent, continuous, peritoneal)*</td>
<td>Intermittent RRT might delay recovery</td>
<td>No effect</td>
</tr>
<tr>
<td>Fluid purity and quality standards</td>
<td>Dialysate purity might affect recovery</td>
<td>No effect</td>
</tr>
<tr>
<td>Membrane type†</td>
<td>Bioincompatible membranes might delay recovery</td>
<td>Bioincompatible membranes might affect recovery</td>
</tr>
<tr>
<td>Anticoagulation</td>
<td>No reported effect on recovery</td>
<td>Uncertain effect</td>
</tr>
<tr>
<td>Haemodynamic stability‡</td>
<td>Hypotension might delay recovery</td>
<td>Uncertain effect</td>
</tr>
<tr>
<td>Mode of solute clearance (diffusion or convection)§</td>
<td>No evidence of effect</td>
<td>No evidence of effect</td>
</tr>
<tr>
<td>Ultrafiltration rate</td>
<td>Rapid fluid removal might delay recovery by causing hypotension</td>
<td>No data</td>
</tr>
<tr>
<td>Fluid Balance§</td>
<td>A positive fluid balance during RRT might delay recovery</td>
<td>A positive fluid balance during RRT might delay recovery</td>
</tr>
<tr>
<td>Dialysate temperature</td>
<td>A cooler dialysate temperature might minimize hypotension and promote recovery</td>
<td>No data</td>
</tr>
<tr>
<td>Dialysate composition</td>
<td>Higher dialysate sodium concentrations might minimize hypotension and thereby promote recovery</td>
<td>No data</td>
</tr>
<tr>
<td>Effect of RRT on other care parameters</td>
<td>RRT might affect drug dosing, nutritional support and nephrotoxin accumulation, which might affect recovery</td>
<td>RRT might affect drug dosing, nutritional support and nephrotoxin accumulation, which might affect recovery</td>
</tr>
<tr>
<td>RRT components (for example, access, circuit, fluid composition)</td>
<td>Possible adverse effect</td>
<td>Unknown</td>
</tr>
<tr>
<td>Dose/intensity (that is, small solute, clearance)#</td>
<td>Level 1 evidence that intensity of solute control does not affect recovery</td>
<td>Level 1 evidence that intensity of solute control does not affect recovery</td>
</tr>
</tbody>
</table>

*Only association studies; one randomized controlled trial (RCT). †Bioincompatible membranes are no longer in use. ‡Based on association. §Small underpowered RCTs. ‖Independent association. ¶No effect of small solute control in two large RCTs. AKI, acute kidney injury; RRT, renal replacement therapy.

---

**Box 7 | Recommendations for the dosing of drugs among patients with AKD**

**Consensus Statement 4A:**

Drug selection, dosing and monitoring among patients with acute kidney disease (AKD) should be guided by the functional phase, trajectory, and stage of AKD as informed by available pertinent data, with the aim to personalize clinical decision-making (evidence grade: level 5).

**Consensus Statement 4B:**

- The decision to discontinue, introduce and/or reintroduce medications in patients with AKD should be individualized (evidence grade: level 5).
- Considerations in selecting a treatment regimen include:
  - Renal versus non-renal excretion
  - Potential for nephrotoxicity
  - Effect of AKD on metabolites and/or the effect of AKD on the non-renal metabolism of drugs
  - The strength of indications and/or urgency for use of the drug
  - The availability of suitable alternatives.

**Consensus statement 4C:**

Ideally, nephrotoxic medications or combinations should be avoided in patients with AKD. When nephrotoxic medications are needed for clinically compelling reasons, efforts should be made to mitigate their nephrotoxic effects with special attention placed on avoiding administering multiple nephrotoxic medications concomitantly when possible (evidence grade: level 5).
Although ACE inhibitors and ARBs have benefits, the risk–benefit ratio in patients with AKD might not reflect that observed in routine clinical practice. Whether stopping these drugs during periods of AKI and/or AKD results in better outcomes, or how often and at what stage they should be restarted following recovery from AKI and/or AKD is not known. Despite recommendations that ACE inhibitors and ARBs are routinely stopped during any intercurrent illness, sparse evidence exists to support these recommendations. Two studies in which these agents were not re-started in patients after surgery demonstrated an increase in 30 day mortality, possibly from hypertensive rebound leading to acute cardiac decompensation. Re-introduction of ACE inhibitors and ARBs in acute illness is usually considered when GFR has stabilized and volume status is optimized. Hypotension and decreased filtration fraction are recognized as common adverse effects associated with ACE inhibitor and ARB use that can cause or exacerbate AKI, and the risk–benefit ratio for their use in patients with AKD must be carefully considered and therapy personalized according to the individual risks of the patient. Although chronic tolerance to reversible decrements in filtration fraction and GFR caused by ACE inhibitors and ARBs might be desirable in patients with chronic heart failure and CKD, such effects might not be tolerable and are without proven benefit in patients with AKD. Similarly, despite a significant risk of potential therapeutic failure caused by under dosing or avoidance of these most

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline risk adjustment</td>
<td>Comorbidities (CKD, CHF, ESLD); interactions with maintenance medications</td>
</tr>
<tr>
<td>Indication and alternatives</td>
<td>Urgency of treatment; therapeutic options; choice of least nephrotoxic drug combination with therapeutic equivalence; risk of harm in case of medication failure</td>
</tr>
<tr>
<td>Drug mechanism</td>
<td>Availability of PK and PD data; alterations in AKD</td>
</tr>
<tr>
<td>Actual renal function</td>
<td>Assessment of renal function using available biomarkers (including serum creatinine, proteinuria, imaging techniques, functional and structural markers in serum and urine)</td>
</tr>
<tr>
<td>Renal reserve</td>
<td>Availability of tests to determine glomerular and tubular reserve</td>
</tr>
<tr>
<td>Non-renal organ dysfunction</td>
<td>Alteration of non-renal clearance; changes in volume of distribution due to extracorporeal circuits (ECMO, VAD)</td>
</tr>
<tr>
<td>Functional genetic susceptibility</td>
<td>Availability of information related to genetic predisposition to nephrotoxicity</td>
</tr>
<tr>
<td>Extra-renal factors</td>
<td>Effects of altered PK and PD of drug metabolites on non-renal organs; assessment of the risk–benefit ratio of drugs affecting renal and non-renal organ systems</td>
</tr>
<tr>
<td>Therapeutic monitoring</td>
<td>Availability of drug levels</td>
</tr>
</tbody>
</table>

AKD, acute kidney disease; CHF, congestive heart failure; CKD, chronic kidney disease; ECMO, extracorporeal membrane oxygenation; ESLD, end-stage liver disease; PD, pharmacodynamics; PK, pharmacokinetics; VAD, ventricular assist device.
effective drugs in patients with AKD (particularly in the recovery phase), such therapeutic failure is rarely recorded\textsuperscript{144}.

**Effect of AKI and AKD on drug metabolism**
The effects of CKD on drug metabolism and subsequent dosing regimens are well established but little is known about the effects of AKI or AKD on drug metabolism\textsuperscript{135}. Extrapolation of data from patients with CKD is not ideal given that the time course of disease progression is different. Organ crosstalk, particularly involving the liver and the kidney, can influence drug metabolism\textsuperscript{135}, which could reflect the impact of AKI on hepatic blood flow, the consequences of metabolic acidosis or changes in protein binding\textsuperscript{136} on drug distribution, and the increasingly recognized effects of AKI on cytochrome P450 activity; overall, the impact of AKI on hepatic drug metabolism seems to be clinically relevant. Impairment of cytochrome P450 activity, as well as effects on drug transporters, could also account for some of the pharmacodynamic effects of AKI.

**Nephrotoxin management during AKD**
In developed countries, drugs account for 20% of community-acquired AKI episodes that result in hospitalization\textsuperscript{137,138}. Drug-associated AKI (DA-AKI) occurs in approximately 25% of critically ill patients, making drugs a common cause of AKI in the ICU\textsuperscript{28,139,140}. The consequences of DA-AKI are severe, with rates of dialysis dependence and/or risk of mortality similar to those of AKI resulting from other aetiologies (40–50%)\textsuperscript{140}. Early reversal of AKI from other aetiologies leads to improved survival compared to that of patients with persistent AKI or new-onset AKI, suggesting that early reversal of DA-AKI might also be associated with improved outcomes\textsuperscript{14}.

Evaluation of nephrotoxins as a plausible cause of AKI is the first consideration in the management of medications for patients with AKI. Determining nephrotoxic causality involves assessment of the temporal sequence between administration and the onset of injury, other possible causes, response to the removal of a drug, and in some cases the effects of restarting the drug\textsuperscript{141}. In all phases of AKD, selection of a less nephrotoxic drug and/or avoidance of a nephrotoxin should be the goal. This approach is supported by the fact that each nephrotoxin administration presents a 53% greater odds of developing AKI\textsuperscript{142}, and is compounded when patients receive more than one nephrotoxin\textsuperscript{143}. Combining nephrotoxins can result in pharmacodynamic drug interactions, such as the ‘triple whammy’ of NSAIDs, diuretics and ACE inhibitors or ARBs\textsuperscript{145}. In the non-ICU setting, escalating the burden of nephrotoxic medications from two to three medications more than doubles the risk of developing AKI, and 25% of non-critically ill patients who receive three or more nephrotoxins develop AKI\textsuperscript{146,144}. Pharmacokinetic drug interactions arising from the administration of some macrolide antibiotics (such as clarithromycin or erythromycin) together with a 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor (statin) result in a greater number of hospitalizations for AKI from rhabdomyolysis, than those arising from administration of azithromycin (a macrolide that does not powerfully inhibit cytochrome p450 enzyme CYP 3A4 and therefore impair statin clearance)\textsuperscript{145}.

An evaluation of the appropriate timing to administer a drug assumes that a nephrotoxin is essential for the patient. The treatment of an infection with an antibiotic that is necessary for survival should begin immediately, and might prevent or ameliorate AKI. Determining whether nephrotoxins are a possible

---

**Table 4 | Timing of drug reinitiation in patients with AKD**

<table>
<thead>
<tr>
<th>AKD Stage</th>
<th>Proximity to AKI event</th>
<th>Renal excretion or active metabolites affected by renal function</th>
<th>Nephrotoxicity</th>
<th>Indications for drug</th>
<th>Availability of suitable alternatives</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Any</td>
<td>Low</td>
<td>Any</td>
<td>Low</td>
<td>Adjust dose as indicated for eGFR</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>&lt;30 days No</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Avoid or withdraw</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>&lt;30 days No</td>
<td>Moderate</td>
<td>High</td>
<td>Low</td>
<td>Start or resume drug but monitor renal function</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>30–90 days No</td>
<td>High</td>
<td>High</td>
<td>Moderate</td>
<td>Start or resume drug but consider lower risk alternatives and monitor</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>&gt;90 days No</td>
<td>Moderate</td>
<td>Low</td>
<td>Moderate</td>
<td>Consider alternatives as overall risk is still likely higher than in the general public</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>&lt;30 days Yes</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Adjust dose as indicated by eGFR but monitor function as steady-state may not have been reached</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30–90 days No</td>
<td>Moderate</td>
<td>High</td>
<td>Moderate</td>
<td>Consider alternatives as overall risk is still likely higher than in the general public</td>
<td></td>
</tr>
<tr>
<td>2–3</td>
<td>30–90 days No</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Avoid</td>
<td></td>
</tr>
<tr>
<td>2–3</td>
<td>&gt;90 days Yes</td>
<td>Low</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Adjust dose as indicated by eGFR but consider alternatives as renal function might be unstable</td>
<td></td>
</tr>
</tbody>
</table>

AKD, acute kidney disease; AKI, acute kidney injury; eGFR, estimated glomerular filtration rate.
cause or contributor to AKI requires thorough evaluation. The persistent phase of AKD necessitates the continued consideration of nephrotoxin avoidance. During the recovery phase of AKD, caution should still be applied to nephrotoxin initiation, to prevent re-injury.

A general statement cannot be made about a functional threshold at which to avoid or discontinue nephrotoxins. The recommendations provided in package inserts or guidelines specific to a drug or drug class might offer guidance. For example, combination trimethoprim and sulfamethoxazole treatment is not recommended if creatinine clearance is <15 ml/min. The revised Beers criteria for potentially inappropriate medication use in older adults indicate moderate evidence to support NSAID avoidance in elderly patients with creatinine clearance <30 ml/min (REF 148).

Detection and management of nephrotoxins at the initiation of AKI146–148,153–155 and during CKD152,153 have been well described but fewer data exist for nephrotoxin management during AKD. Two groups reported together on a multicomponent medical management approach to patients following an episode of AKI, including the management of drugs. Patients are educated to avoid taking NSAIDs (or any new medications) without consulting their nephrologist, and to use ACE inhibitors, decongestants, antivirals, antibiotics and herbal products with caution158.

Conclusions

AKD represents an important transition period for patients who have suffered an episode of AKI. Considerable advances have been made in our collective understanding of AKI and CKD; however, the relationship between these two conditions is vitally important because these two syndromes are interconnected. One of the most significant risk factors for AKI is pre-existing CKD, and AKI is a significant risk factor for the development of CKD as well as the progression of pre-existing CKD. A critical period of vulnerability for patients who develop AKI is in the immediate period following development of AKI — a period previously labelled AKD. In this manuscript, the ADQI workgroup offers a series of proposed definitions and recommendations that aim to increase awareness of AKD and encourage research that will guide future understanding of the epidemiology, mechanisms and management of AKD.

As we have proposed new definitions, provided guidance for clinical practice and put forth a large agenda for future research, it will be incumbent on the AKI clinical research community to test our recommendations. Importantly, as many patients with AKI present to the hospital with ongoing AKI, a critical intervention point to facilitate recovery and minimize continuing damage will occur during AKD. As such, the ADQI 16 workgroup advocates a sense of urgency behind both the adoption of our clinical recommendations and the execution of the proposed research agenda.
CONSENSUS STATEMENT


Xie, M. & Iqbal, S. Predictors for nephrology outpatient care and recurrence of acute kidney injury (AKI) after an in-hospital AKI episode. Hemodial. Int. 18 (Suppl. 1), S7–S12 (2014).


Author contributions
All authors made equal contributions to discussion of content and research data for the article. L.S.C., R.B., A.B., S.L.G. and E.H. wrote the article and L.S.C., R.B., S.L.G., S.M.B. and C.R. reviewed/edited the manuscript before submission.

Competing interests statement
L.S.C. has received consulting fees from Astute Medical, Nxtstage Medical and Bard Medical. R.B. has received research support from Baxter Medical. A.B. has received research support from Astute Medical, INC and the Society of Critical Care Medicine. S.L.G. has received grants from Gambro Renal Products, Vitalio, Mallinckrodt, and Alexion; grants and personal fees from Baxter Healthcare, Astute Medical, Bellco, AM Pharma, and La Jolla Pharmaceuticals; and personal fees from Biopore, Aekuba, Otukana, Kaneka, and Medibeacon, all outside the submitted work. S.M.B. has received consulting fees from Baxter and La Jolla Pharmaceuticals. L.F. has received receiving consulting fees from Fresenius, Astute Medical, Eras Pharma, Baxter, and Ortho Clinical. E.H. has received speaker’s fees from Alexion and a research grant from Bellco. J.K. has received consulting fees from Nxtstage Medical, Astute Medical, Spingoteck and Pfizer. E.M. has received research funding from Relypsa and Fresenius Kabib. R.M. has received consulting fees from Eli Lilly, Spectral, Keryx, Baxter, Ardea, AM Pharma, GSK, CSL Behring, Grifols, Astute Inc. Fresenius Kabib, Quark, Ferring Research, Ionis Pharmaceuticals, Johnsons and Johnson and DURECT, and has received research support from iSACG, Relypsa, Fresenius-Kabi and Fresenius. M.O. has received speaker honoraria and research funding from Fresenius Medical Care, and payment for advisory services from Baxter/Gambro. P.M.P has received consulting fees from Durect and Baxter. R.W. has received consulting fees from Durect and Medbeacon and unrestricted research support from Baxter. A.Z. has received unrestricted research grants from Fresenius and Astute Medical and lecture fees from Fresenius, Braun, Astute Medical, and Astellas. C.R. has received consulting fees from Astute, Alohi, CE and Baxter. J.A.K. has received consulting fees from Astute Medical, Atoio, Bio, Astellas, Bard Medical, Baxter Medical, Biopore, Grifolds, Medibeacon and Nxtstage Medical E.D.S. D.B., D.C., Z.E., P.L.F, S.I.K.G., K.D.L., P.M., N.P. and M.R. declare no competing interests.

SUPPLEMENTARY INFORMATION
See online articles: | S2 (table) | S3 (table) | S4 (table) | S5 (table) | S6 (table) | S7 (table) |

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line, if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.